12.22.25 -- Cell & Gene Therapy Outsourcing's New Paradigm

Accelerating the development of adoptive cell therapies through robust preclinical strategies and regulatory pathways is crucial to bringing these life-saving treatments to patients in need.

Learn how a platform streamlines LVV titer measurement, offering a faster and more efficient alternative to traditional methods and addressing key process development challenges.

Discover how the evolution of T7 polymerase is optimizing in vitro transcription for RNA therapeutics. See how to balance performance, cost, and supply to make smart choices for your xRNA manufacturing.

Unvalidated shipping lanes and incomplete documentation can cause regulatory delays. Proactive qualification and risk assessments are vital for compliance and safeguarding product integrity.

Examine how nanoplate-based digital PCR streamlines AAV titering, providing faster results and greater accuracy, advancing gene therapy development from the lab to the clinic.

Become equipped with the tools and strategies needed to strengthen your calibration efforts and better position your organization for success in regulatory audits.

Ensure your business stays ahead in today’s complex regulatory environment by implementing robust regulatory affairs strategies that streamline compliance and product approvals.

When choosing between protein expression formats such as transient versus stable pools, considerations include speed, cost, titre, and product quality.

Assimilate how high-speed isolator lines enable sterile, scalable manufacturing for complex biologics and injectables with unmatched efficiency and product integrity.

Explore how one family's collaboration with a specialized CDMO enabled the rapid development of a life-saving gene therapy for their daughter diagnosed with an ultra-rare disease.